Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science



Rating:

Share or cite this content

Citations should be made in the following way:
H. Heatley (Singapore, Singapore), T. Tran (Gaithersburg, United States of America), A. Bourdin (Montpellier, France), A. Menzies-Gow (London, United Kingdom), D. Jackson (London, United Kingdom), E. Maslova (Cambridge, United Kingdom), D. Skinner (Singapore, Singapore), V. Carter (Singapore, Singapore), D. Price (Singapore, Singapore). Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma. 1491

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019 Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy. Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Oral corticosteroid (OCS) risk predictor for osteoporosis Source: Virtual Congress 2021 – Lung disease burden and management Year: 2021 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Late Breaking Abstract - Overuse of oral corticosteroids in asthma – modifiable factors and potential role of biologics Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - Effect of inhaled corticosteroids on exacerbation of asthma–COPD overlap according to different diagnostic criteria Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Is there a problem with oral corticosteroid use in asthma? Source: Virtual Congress 2020 – Airway diseases Year: 2020 Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Late Breaking Abstract: Fluticasone/salmeterol combination confers significant benefits in smoking asthmatics Source: Annual Congress 2010 - Smoking related diseases, damages due to environmental tobacco smoke and smoking control strategies Year: 2010 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Explore the effective dose of bronchodilator nebulization via high flow nasal cannula in adult COPD and asthma patients Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018